50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
New Shift Could Soon Affect All Americans (Ad)pixel
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
New Shift Could Soon Affect All Americans (Ad)pixel
Dow sinks to 2022 low as recession fears roil world markets
MarketBeat: Week in Review 9/19 – 9/23
What’s the Obsession Over Inflation? (Ad)pixel
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
New Shift Could Soon Affect All Americans (Ad)pixel
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
New Shift Could Soon Affect All Americans (Ad)pixel
Dow sinks to 2022 low as recession fears roil world markets
MarketBeat: Week in Review 9/19 – 9/23
What’s the Obsession Over Inflation? (Ad)pixel
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
New Shift Could Soon Affect All Americans (Ad)pixel
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
New Shift Could Soon Affect All Americans (Ad)pixel
Dow sinks to 2022 low as recession fears roil world markets
MarketBeat: Week in Review 9/19 – 9/23
What’s the Obsession Over Inflation? (Ad)pixel
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
New Shift Could Soon Affect All Americans (Ad)pixel
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
New Shift Could Soon Affect All Americans (Ad)pixel
Dow sinks to 2022 low as recession fears roil world markets
MarketBeat: Week in Review 9/19 – 9/23
What’s the Obsession Over Inflation? (Ad)pixel
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
ETR:MOR

MorphoSys - MOR Stock Forecast, Price & News

€18.17
-0.41 (-2.21%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
€17.80
€18.79
50-Day Range
€16.54
€24.03
52-Week Range
€16.08
€43.29
Volume
119,708 shs
Average Volume
153,687 shs
Market Capitalization
$620.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
€43.92
MOR stock logo

About MorphoSys (ETR:MOR) Stock

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Receive MOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter.

MOR Stock News Headlines

Here's How Criteo Fared In Q1
See More Headlines
Receive MOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter.

MOR Company Calendar

Today
9/24/2022
Next Earnings (Estimated)
11/16/2022

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
732
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
€43.92
High Stock Price Forecast
€76.00
Low Stock Price Forecast
€24.00
Forecasted Upside/Downside
+141.7%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$195.10 million
Cash Flow
€20.81 per share
Book Value
(€0.80) per share

Miscellaneous

Free Float
N/A
Market Cap
$620.57 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Jean-Paul Kress M.D. (Age 57)
    Chairman of Management Board, MD & CEO
    Comp: $1.94M
  • Mr. Sung H. Lee (Age 52)
    CFO & Member of Management Board
    Comp: $488.7k
  • Dr. Malte Peters M.D. (Age 60)
    Chief R&D Officer and Member of the Management Board
    Comp: $1.15M
  • Dr. Marlies Sproll (Age 64)
    Special Adviser to the Chief Exec. Officer
  • Mr. Klaus De Wall
    Head of Accounting & Tax
  • Ms. Lara Smith Weber
    Head of Controlling, Corp. Fin. & Corp. Devel.
  • Dr. Margit Urban
    Head of Discovery Alliances & Technologies
  • Dr. Anja Pomrehn
    Sr. VP & Head of Investor Relations
  • Ms. Charlotte Lohmann (Age 52)
    Sr. VP of Legal, Compliance & IP and Gen. Counsel
  • Mr. Thomas Biegi
    VP & Head of Corp. Communications













MOR Stock - Frequently Asked Questions

What is MorphoSys' stock price forecast for 2022?

0 Wall Street research analysts have issued 12 month price objectives for MorphoSys' stock. Their MOR share price forecasts range from €24.00 to €76.00. On average, they predict the company's stock price to reach €43.92 in the next year. This suggests a possible upside of 141.7% from the stock's current price.
View analysts price targets for MOR
or view top-rated stocks among Wall Street analysts.

How have MOR shares performed in 2022?

MorphoSys' stock was trading at €33.35 on January 1st, 2022. Since then, MOR shares have decreased by 45.5% and is now trading at €18.17.
View the best growth stocks for 2022 here
.

When is MorphoSys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 16th 2022.
View our MOR earnings forecast
.

What other stocks do shareholders of MorphoSys own?
What is MorphoSys' stock symbol?

MorphoSys trades on the ETR under the ticker symbol "MOR."

What is MorphoSys' stock price today?

One share of MOR stock can currently be purchased for approximately €18.17.

How much money does MorphoSys make?

MorphoSys (ETR:MOR) has a market capitalization of $620.57 million and generates $195.10 million in revenue each year.

How many employees does MorphoSys have?

The company employs 732 workers across the globe.

How can I contact MorphoSys?

MorphoSys' mailing address is Semmelweisstr. 7, PLANEGG, 82152, Germany. The official website for the company is www.morphosys.de. The company can be reached via phone at +49-89-899270.

This page (ETR:MOR) was last updated on 9/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.